Literature DB >> 3535252

Development of immunoglobulin preparations for intravenous use.

S Barandun, H Isliker.   

Abstract

Mesh:

Substances:

Year:  1986        PMID: 3535252     DOI: 10.1111/j.1423-0410.1986.tb00235.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


× No keyword cloud information.
  6 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 2.  Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts.

Authors:  P P Sanna; D R Burton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Hypothesis: hemolytic transfusion reactions represent an alternative type of anaphylaxis.

Authors:  Eldad A Hod; Set A Sokol; James C Zimring; Steven L Spitalnik
Journal:  Int J Clin Exp Pathol       Date:  2008-05-30

Review 4.  The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative.

Authors:  Albert Farrugia; Giuliano Grazzini; Isabella Quinti; Fabio Candura; Samantha Profili; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

5.  Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model.

Authors:  W K Bleeker; J Agterberg; G Rigter; N van Rooijen; J C Bakker
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

6.  Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.

Authors:  M Ballow
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.